Axol Bioscience is proud to collaborate with the University of Melbourne, Chromos Labs, Tessara Therapeutics, and Quantum Brilliance on a newly funded $2.1M AUD initiative supported by the Australian Government. The consortium is developing a quantum‑enabled brain‑on‑chip platform designed to accelerate the discovery and development of treatments for Alzheimer’s disease and other neurological conditions.

This next‑generation platform integrates 3D human neural micro‑tissues with diamond‑based quantum sensing, enabling real‑time measurements of electrical activity in physiologically relevant brain models. This quantum approach provides the high‑resolution functional insights needed to de‑risk and accelerate neurological drug development.

Our CEO, Liam Taylor, shared:

“Axol is proud to be supporting and providing critical biological infrastructure that enables Australian, in this case Victorian, research. This project brings together our iPSC‑derived models with 3D human neural micro‑tissues and a quantum‑enabled platform that measures real‑time electrical activity, marking an important step forward for neuroscience research.”

You can read the full announcement from the University of Melbourne here: https://www.unimelb.edu.au/newsroom/news/2026/march/australian-consortium-to-develop-quantum-biotechnology-platform-to-transform-alzheimers-treatment-discovery